Genetic Variants and Their Implications in Gynecologic Cancers

Introduction

Gynecologic cancers are more likely to be caused by genetic causes than other types of cancer. A promising new approach to cancer prevention, diagnosis, and treatment is genetic testing. This review elucidates the molecular characteristics of gynecologic malignancies associated with hereditary syndromes. Hereditary ovarian and breast cancer, Cowden syndrome (Cowden syndrome is an autosomal dominant inherited condition characterized by benign overgrowths called hamartomas), Lynch syndrome (hereditary nonpolyposis colorectal cancer), and Peutz-Jeghers syndrome (autosomal dominant genetic disorder) are common hereditary gynecologic cancers.

What Are Gynecological Cancers?

Breast, ovarian, and endometrial cancers are examples of hereditary gynecologic malignancies, along with a few other uncommon diseases of the female reproductive system. A pathogenic mutation in a cancer-related gene has been found to significantly increase the lifetime risk of developing cancer 2. 5 to 10 percent of breast, ovarian, and endometrial cancers are caused by pathogenic mutations in gynecologic cancer predisposition genes combined. Carriers of these variations have a notably higher lifetime chance of acquiring cancer (up to 72 percent).

How Are Genetic Mutations Linked to Gynecologic Cancer?

Gene mutations are similar to typos in a gene's genetic code. A gene mutation may put a person at higher risk than usual of getting some types of cancer. Certain families have a genetic mutation that raises the risk of gynecologic cancer.

Endometrial Cancer and Genetic Mutations:

TGBR2, PMS1, PMS2, MLH1, MSH2, MLH3, and MSH6: These gene mutations are a component of Lynch syndrome, another name for the cancer syndrome known as hereditary non-polyposis colorectal cancer (HNPCC). This syndrome increases the risk of colorectal cancer, as the name implies, but it also increases the risk of endometrial, ovarian, stomach, and several other cancers. This syndrome puts women at up to 70 percent risk of endometrial cancer in the future.

Genetic Mutations Linked to Ovarian Cancer:

1. BRCA1 and BRCA2: Hereditary breast and ovarian cancer syndrome is caused by mutations in the BRCA1 and BRCA2 genes. This syndrome has been associated with an increased risk of primary peritoneal cancer, breast cancer, fallopian tube cancer, and ovarian cancer. Additionally, there is an increased chance of developing some other malignancies, such as pancreatic cancer and prostate cancer.

2. MLH1, MSH2, MSH6, PMS2, and EPCAM: The gene mutations MutL protein homolog 1, MutL protein homolog 2, MutL protein homolog 6, postmeiotic segregation increased 2, and epithelial cellular adhesion molecule is associated with a cancer syndrome known as Lynch syndrome or hereditary non-polyposis colorectal cancer (HNPCC). Up to 10 percent of women with this disease will eventually develop ovarian cancer.

3. STK11 Gene: During adolescence, this syndrome results in polyps in the intestines and stomach. This syndrome increases the risk of developing several malignancies, including stomach, esophageal, colon, and small intestine tumors. Ovarian cancer is more common in women with this condition.

4. MUTYH: Polyps in the colon and small intestine are also brought on by this gene mutation. This gene mutation increases the risk of bladder and ovarian cancer in addition to colon cancer.

5. RAD51 Paralog D, and Partner and Localizer of BRCA2: These have been associated with breast and pancreatic malignancies in addition to ovarian cancer.

What Are the Risks Factors for Gynecological Cancers?

Breast cancer and gynecologic cancer may have a hereditary component due to the following factors:

1. A higher incidence of these cancers in people with a family history of these diseases.

2. Multiple family members affected by these and other diseases.

3. A pattern of cancers consistent with autosomal dominant inheritance. An autosomal dominant gene linked to cancer predisposition can be inherited and passed down by both sexes.

In addition to a person's family history, other factors that can impact cancer risk include reproductive history, usage of oral contraceptives and hormone replacement therapy, early radiation exposure, alcohol intake, and physical activity.

What Are the Associated Genes and Syndromes?

Several autosomal dominant cancer syndromes include breast and ovarian cancer, with highly penetrant germline pathogenic mutations in BRCA1 and BRCA2. Other genes that confer a relatively high penetrance risk to either or both of these cancers include PALB2, TP53 (linked to Li-Fraumeni syndrome), PTEN (linked to PTEN hamartoma tumor syndromes, including Cowden syndrome), CDH1 (linked to diffuse gastric and lobular breast cancer syndrome), and STK11 (linked to Peutz-Jeghers syndrome).

The Lynch syndrome, which is brought on by inherited pathogenic variations in the highly penetrant mismatch repair genes MLH1, MSH2, MSH6, PMS2, and EPCAM, is most frequently linked to inherited endometrial cancer. Lynch is also linked to colorectal cancer (and, to a lesser extent, ovarian and stomach cancer).

What Are the Treatments for Gynecological Cancers?

Medical Therapy:

Breast cancer screening methods, such as mammography and breast magnetic resonance imaging, are frequently used on BRCA pathogenic variant carriers and those who are at higher risk of developing the disease. It is typically advised that screening begin earlier in life and more frequently in those who have a genetic or family history that puts them at higher risk than the general population. In carriers of BRCA1 and BRCA2 pathogenic mutations, risk-reducing operations, such as risk-reducing salpingo-oophorectomy (RRSO) and risk-reducing mastectomy (RRM), have been demonstrated to increase overall survival and considerably lower the likelihood of getting breast or ovarian cancer. Strategies for ovarian cancer and breast cancer chemoprevention have been studied in this population.

Behavioral and Psychosocial Problems:

Decisions regarding risk-management techniques and genetic testing for inherited cancer risk are influenced by psychosocial variables. Perceived risk of getting breast or ovarian cancer and cancer-specific suffering are two psychological factors linked to testing uptake. Low levels of distress following genetic testing have been observed, especially in the long run, for both carriers and noncarriers. Patients' sharing of information with their family members regarding a hereditary risk of gynecologic and breast cancer can be complicated; factors that influence this disclosure include age, gender, and the degree of relatedness. To comprehend and treat psychosocial and behavioral problems in high-risk families more effectively, research is still being conducted.

Surgical Methods for Treating Cancer:

Every woman's experience with gynecologic cancer is unique, and surgery is frequently a component of the treatment plan to remove the tumor as much as possible. Because there will be fewer tumors to treat, shrinking the tumor increases the effectiveness of any chemotherapy or radiation therapy that comes after it.

For gynecologic malignancies, surgical techniques include:

1. Debulking Surgery: It involves removing as much of the tumor as feasible, usually in advance of chemotherapy, to reduce the amount of tumor that needs to be treated. The most common uses of this method are for primary peritoneal, fallopian tube, and ovarian malignancies.

2. Complete Hysterectomy: Both the uterus and the cervix are removed.

3. Radical Hysterectomy: A radical hysterectomy involves removing the fallopian tubes, ovaries, and any adjacent lymph nodes in addition to the uterus, cervix, and a portion of the vagina.

4. Unilateral Salpingo-Oophorectomy: One ovary and one fallopian tube are removed during a unilateral salpingo-oophorectomy.

5. Bilateral Salpingo-Oophorectomy: A bilateral salpingo-oophorectomy involves the removal of both fallopian tubes and ovaries.

6. Omentectomy: The removal of the abdominal cavity's omentum, a fat pad.

7. Removal of Lymph Nodes: This involves removing some or all cancer-affected lymph nodes.

8. Radical vulvectomy: Removes malignant growth growing on the vulva skin (a radical vulvectomy).

9. Radical Trachelectomy: Surgery for cervical cancer that preserves fertility, also known as a radical trachelectomy; this procedure allows the cervix to be removed while leaving the uterus, ovaries, and fallopian tube intact.

Medication-Assisted Gynecologic Cancer Treatment:

Depending on the kind and stage of the illness, some women with gynecologic cancer may be eligible for medication-assisted cancer therapy. Gynecologic oncologists may recommend:

1. Chemotherapy: Injectable or oral medications are used to destroy cancer cells.

2. Immunotherapy: Boosts the body's defenses against gynecologic cancer by stimulating the immune system.

3. Hormone Therapy: Prevents and treats some gynecologic malignancies by using hormones.

Chemotherapy medications are administered intraperitoneally, a complex and unusual procedure that uses a catheter to enter the abdominal cavity and deliver the chemicals.

Radiation Treatment:

Whether it is used as an adjuvant therapy after surgery or as a primary/curative treatment, radiation therapy is a necessary treatment for the majority of gynecologic malignancies.

Conclusion

Every gynecologic cancer is unique, exhibiting a unique combination of warning signs and symptoms, risk factors (items that increase the likelihood of contracting the disease), and preventive measures. All women are at risk for gynecologic cancer, and the risk increases with age. Gynecological cancers are breast, ovarian, and endometrial cancers, as well as another rare cancer that is related to the female reproductive tract. This can be due to gene changes controlling cell growth and multiplying.